Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
about
Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis.Applicability of graded prognostic assessment of lung cancer using molecular markers to lung adenocarcinoma patients with brain metastases.Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery.Prospective study of 11C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment.The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated non-small cell lung cancer.Can we omit radiotherapy in case of brain metastases for patients with mutant EGFR lung adenocarcinoma?Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation.Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score.Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001.Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?Predicting prognosis of short survival time after palliative whole-brain radiotherapy.Imaging and clinical end points in brain metastases trials.Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.Prognostic value of cancer antigen -125 for lung adenocarcinoma patients with brain metastasis: A random survival forest prognostic model.Role of Recursive Partitioning Analysis and Graded Prognostic Assessment on Identifying Non-Small Cell Lung Cancer Patients with Brain Metastases Who May Benefit from Postradiation Systemic Therapy.Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions.Mechanisms and Therapy for Cancer Metastasis to the Brain.Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer.MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.Strategies to Preserve Cognition in Patients With Brain Metastases: A ReviewIdentification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics AnalysisBrain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer PatientsThe Expanding Role of Radiosurgery for Brain MetastasesGAP43, a novel metastasis promoter in non-small cell lung cancer
P2860
Q33832902-77810134-3288-456C-8661-BBDA4F457135Q37742623-60750A61-124A-492E-BA3F-4A0E253BFB83Q40049272-060E04FC-78CD-4C96-9AA1-3AE74632252CQ42378468-EB67EC85-A106-4DEB-880F-C546DBFF0840Q47102842-D2760C6B-8120-4986-BFAE-3AC53327C633Q47109146-4CCECBF9-AD1C-41BB-A8B6-C4F871725EE0Q47119162-12029EB9-912C-4B26-B1F4-579E17096FF9Q47151436-5502768E-EFA9-4E84-9BD5-2D73AEE0CD99Q47426457-0279DD30-7012-4999-B184-F4ABBFA0B815Q47860971-121E492B-01B1-4A75-8E32-1DDB474B1B1DQ47898300-36B5361A-3E05-40A7-93C1-5CD6A348AB9AQ47899183-BBE20A06-C8B8-482A-B4D0-C8823E1BCA05Q48001323-D407AD30-C78D-4918-BB09-9AC17F9F60C3Q48031513-57FAB03D-234B-47EC-B805-EFD00F20D4DAQ52318443-6A2A7831-937C-479D-B579-5EC87728C807Q52606350-8C62BB8C-A352-4B8C-A999-971ED1BC8C8FQ54112682-D6BFD1AA-1F14-44F8-8DB0-964E79F6A345Q54942435-31407BC6-4327-449A-B94C-73C812B4E60BQ54950354-142A3DF0-E285-47B4-A898-F52BB29D16CFQ55129503-E0230173-D472-4952-8F0F-BA6D4CCDCA6EQ55360749-8DC3C59E-3A04-402A-829D-FD70917C92B7Q57816905-36EF5303-CCFB-40A6-AA35-63CF461A7234Q58122535-3B2548D3-10D4-4141-8913-14A7602CCC7DQ58762991-F54222E5-CDE7-4B3B-A4B5-787AC9A89197Q58779547-EB21F3B6-CE39-47F7-9086-FF3E05DE89FDQ59136212-A358DDB6-779C-4C2E-AB80-25E6D48D9697
P2860
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Estimating Survival in Patient ...... lecular Markers (Lung-molGPA).
@en
type
label
Estimating Survival in Patient ...... lecular Markers (Lung-molGPA).
@en
prefLabel
Estimating Survival in Patient ...... lecular Markers (Lung-molGPA).
@en
P2093
P2860
P50
P1433
P1476
Estimating Survival in Patient ...... olecular Markers (Lung-molGPA)
@en
P2093
Alex Engelman
Ananta Bangdiwala
Brian Alexander
David Roberge
Hubert Pan
John Boyle
John Hardie
John P Kirkpatrick
P2860
P304
P356
10.1001/JAMAONCOL.2016.3834
P577
2017-06-01T00:00:00Z